Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Slides:

Advertisements

Similar presentations

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Advertisements

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial Åsa Lindholm,

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis Konstantinos A. Toulis, M.D.,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study Carolyn Gibson, M.P.H., M.S., Karen Matthews,

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

MRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome.

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Michael M. Alper, M.D. Fertility and Sterility

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Effect of a very-low-calorie diet on in vitro fertilization outcomes

Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Functional neuroimaging of emotional processing in women with polycystic ovary syndrome: a case-control pilot study Courtney A. Marsh, M.D., M.P.H.,

Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome Héctor F. Escobar-Morreale,

Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral.

Evolutionary determinants of polycystic ovary syndrome: part 1

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Pernille Fog Svendsen, M. D. , Michael Christiansen, M. D

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity Jean-Patrice Baillargeon, M.D.,

Ovulation induction in women with polycystic ovary syndrome

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Prevalence of polycystic ovary syndrome in Chinese obese women of reproductive age with or without metabolic syndrome Peiwen Liang, M.D., Liuqing Xi,

Increased secretion of amylin in women with polycystic ovary syndrome

ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome Lucas Bandeira Marchesan, B.Sc., Poli Mara Spritzer,

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a.

Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic.

Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation Allison Styne-Gross, M.D., Karen.

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Serum resistin levels in women with polycystic ovary syndrome

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions Kristen Farrell, M.S.,

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Current evaluation of amenorrhea

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy Helena J. Teede, Ph.D., Caroline Meyer, Ph.D.,

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome Robert P. Kauffman,

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis

Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?

Presentation transcript:

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels Dimitrios Panidis, M.D., Ph.D., Dimitrios Farmakiotis, M.D., David Rousso, M.D., Anargyros Kourtis, M.D., Ilias Katsikis, M.D., Gerassimos Krassas, M.D. Fertility and Sterility Volume 89, Issue 4, Pages 899-906 (April 2008) DOI: 10.1016/j.fertnstert.2007.04.043 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Changes in BMI for obese women with PCOS, compared with obese control women (mean ± SEM). BL = baseline. ∗Significant effect of time: P<.05 vs. previous value. Fertility and Sterility 2008 89, 899-906DOI: (10.1016/j.fertnstert.2007.04.043) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Changes in total T levels for obese women with PCOS, compared with obese control women (mean ± SEM). BL = baseline. ∗Significant effect of time and interaction: P<.05 vs. previous value in women with PCOS, significant change compared with the control group. †Significant effect of PCOS: P<.05 vs. control women. Fertility and Sterility 2008 89, 899-906DOI: (10.1016/j.fertnstert.2007.04.043) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Changes in HOMA-IR values for obese women with PCOS, compared with obese control women (mean ± SEM). BL = baseline. ∗Significant effect of time: P<.05 vs. previous value in women with PCOS, P<.05 vs. baseline in control women. Interaction P (baseline → 12 wks)=.051. Fertility and Sterility 2008 89, 899-906DOI: (10.1016/j.fertnstert.2007.04.043) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions